ABSTRACT
The utilization of rHuEp changed definitively the treatment and the natural history of anemia in patients with chronic renal insufficiency (CRI), and now is modifying the treatment of anemia of other non-renal patients as anemia of premature, anemia in onco-hematological illnesses, anemia in human immunodeficiency virus (HIV) infection, and for reduction of allogenic blood transfusions in surgery. We analyze briefly the clinical indications of rHuEpo and the possible complications secondary to its use.
Subject(s)
Anemia/drug therapy , Erythropoietin/therapeutic use , Anemia/etiology , Humans , Kidney Failure, Chronic/complicationsABSTRACT
El empleo de la eritropoyetina recombinante (rHuEp) modificó definitivamente el tratamiento y el curso evolutivo de la anemia del paciente con insuficiencia renal crónica (IRC) y está modificando el tratamiento de la anemia de otros pacientes no renales como anemias del prematuro, padecimientos oncohematológicos, infección por el virus de la inmunodeficiencia humana (VIH) y reducción de las transfusiones de sangre alogénica en cirugía. En el presente trabajo analizamos brevemente las indicaciones clínicas de la rHuEpo y las posibles complicaciones derivadas de su empleo
The utilization of rHuEp changed definitively the treatment and the natural history of anemia in patients with chronic renal insufficiency (CRI), and now is modifying the treatment of anemia of other non-renal patients as anemia of premature, anemia in onco-hematological illnesses, anemia in human immunodeficiency virus (HIV) infection, and for reduction of allogenic blood transfusions in surgery. We analyze briefly the clinical indications of rHuEpo and the possible complications secondary to its use
